We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PASI 100 response to secukinumab in primary failure to ustekinumab: analysis of cost‐effectiveness among biological drugs.
- Authors
de Oliveira, Maria de Fátima P.; Rocha, Bruno de O.; Duarte, Gleison V.
- Abstract
Dear Editor, A 32-year-old male patient diagnosed with psoriasis since the age of 15 presented to our clinic in April 2013, with PASI = 24 and severe nail injuries. The present case demonstrates a patient with skin psoriasis without improvement under use of classical treatments and phototherapy, with primary failure to UST treatment but rapid and sustained response to SEK. Psoriasis treatment goals are complex to achieve, requiring not only PASI 90 and DLQI < 5 but also management of comorbid conditions. The current case reports an overweight, dyslipidemic patient with severe cutaneous psoriasis, presenting primary failure to UST but achieving PASI 100 response after switching to SEK.
- Subjects
FAILURE analysis; PSORIATIC arthritis; COST effectiveness
- Publication
International Journal of Dermatology, 2021, Vol 60, Issue 9, p1165
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.15493